2011
DOI: 10.1001/archdermatol.2011.47
|View full text |Cite
|
Sign up to set email alerts
|

Benign Dermoscopic Parallel Ridge Pattern Variants

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
13
0

Year Published

2013
2013
2019
2019

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 12 publications
(14 citation statements)
references
References 0 publications
0
13
0
Order By: Relevance
“…11,12 The main finding of this study was that the use of DHA can lead to temporary changes in dermoscopic features in PSLs. 11,12 The main finding of this study was that the use of DHA can lead to temporary changes in dermoscopic features in PSLs.…”
Section: Discussionmentioning
confidence: 81%
See 3 more Smart Citations
“…11,12 The main finding of this study was that the use of DHA can lead to temporary changes in dermoscopic features in PSLs. 11,12 The main finding of this study was that the use of DHA can lead to temporary changes in dermoscopic features in PSLs.…”
Section: Discussionmentioning
confidence: 81%
“…Previous reports have shown that DHA can affect dermoscopy and even simulate MM. 11,12 The main finding of this study was that the use of DHA can lead to temporary changes in dermoscopic features in PSLs. For facial SL ⁄ISK there may be a risk that the use of DHA can affect the dermoscopic diagnosis and clinical management, because FP was seen after application of DHA.…”
Section: Discussionmentioning
confidence: 81%
See 2 more Smart Citations
“…For example, patients undergoing systemic psoriasis treatments often face issues of access (eg, treatment expense, delays in obtaining insurance approvals to continue treatment or lack of insurance approval to increase the dose of treatment owing to suboptimal response, and difficulty in traveling to offices that provide psoriasis treatment) and tachyphylaxis, and often patients express safety concerns that result in treatment discontinuation. 3 In addition, prior treatment experience, which may inform response rates, may not be reflected in clinical trials (eg, the ACCEPT 4 …”
mentioning
confidence: 99%